Burden of herpes zoster requiring hospitalization in Spain during a seven-year period (1998–2004) by Gil, Angel et al.
BioMed  Central
Page 1 of 5
(page number not for citation purposes)
BMC Infectious Diseases
Open Access Research article
Burden of herpes zoster requiring hospitalization in Spain during a 
seven-year period (1998–2004)
Angel Gil*1, Ruth Gil1, Alejendro Alvaro1, María San Martín2 and 
Antonio González2
Address: 1Department of Health Sciences, Rey Juan Carlos University, Avda de Atenas s/n, 28922 Alcorcón, Madrid, Spain and 2Medical 
Department, Sanofi Pasteur MSD, P° de la Castellana 141, 28046 Madrid, Spain
Email: Angel Gil* - angel.gil@urjc.es; Ruth Gil - ruth.gil@urjc.es; Alejendro Alvaro - alejandro.alvaro@urjc.es; María San 
Martín - msanmartinrodriguez@spmsd.com; Antonio González - agonzalezlopez@spmsd.com
* Corresponding author    
Abstract
Background: A thorough epidemiological surveillance and a good understanding of the burden of
diseases associated to VZV are crucial to asses any potential impact of a prevention strategy. A
population-based retrospective epidemiological study to estimate the burden of herpes zoster
requiring hospitalization in Spain was conducted.
Methods: This study was conducted by using data from the national surveillance system for
hospital data, Conjunto Mínimo Básico de Datos (CMBD). Records of all patients admitted to
hospital with a diagnosis of herpes zoster (ICD-9-MC codes 053.0–053.9) during a 7-year period
(1998–2004) were selected.
Results: A total of 23,584 hospitalizations with a primary or secondary diagnosis of herpes zoster
in patients ≥ 30 years of age were identified during the study period. Annually there were 13.4
hospitalizations for herpes zoster per 100,000 population in patients ≥ 30 years of age. The rate
increases with age reaching a maximum in persons ≥ 80 years of age (54.3 admissions per 100,000
population >80 years of age). The mean cost of a hospitalization for herpes zoster in adult patients
was 3,720 €. The estimated annual cost of hospitalizations for herpes zoster in patients ≥ 30 years
of age in Spain was 12,731,954 €.
Conclusion: Herpes zoster imposes an important burden of hospitalizations and result in large
cost expenses to the Spanish National Health System, especially in population older than 50 years
of age
Background
It is estimated that the 15% of the population will suffer
from herpes zoster (HZ) at least once in their lifetime [1].
Complications of herpes zoster occurs in 13–26% of the
cases [2,3]. Post-herpetic neuralgia (PHN) is the most
common and debilitating [4,5], affecting 15 to 40% of
cases. [3,6]. The incidence and severity of herpes zoster
and postherpetic neuralgia increase with age due to the
depletion of cell-mediated immunity to Varicella-Zoster
Virus (VZV). Complications are associated with excess of
morbidity, but also are thought to be associated with an
increase of the costs for the health care system.
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An effective and safe, live attenuated varicella-zoster virus
vaccine has proved to reduce the burden of illness due to
herpes zoster among people 60 years of age or older, as
well as the morbidity from post-herpetic neuralgia among
older adults [7]. A thorough epidemiological surveillance
and a good understanding of the burden of diseases asso-
ciated to VZV are crucial to asses any potential impact of a
prevention strategy.
Hospital discharge databases provide a complete record of
all hospitalizations and are not subject to under-diagnosis
and deficiencies in reporting that usually limit surveil-
lance systems of outpatient diseases. Additionally, hospi-
talization databases measure the most severe part of the
disease spectrum, herpes zoster in this case [8].
The aim of this study was to estimate the burden of hospi-
tal admissions for herpes zoster in persons ≥ 30 years of
age, in Spain during a 7-years period (1998–2004).
Methods
A retrospective study was conducted by using discharge
information obtained from the national surveillance sys-
tem for hospital data maintained by the Ministry of
Health, Conjunto Mínimo Básico de Datos (CMBD). This
database records all hospital admissions, with an esti-
mated coverage of 97.7% in public hospitals and 25% in
private clinics [9,10]. However, private hospitals represent
a small proportion of all hospital admissions, as public
healthcare insurance is covering almost 100% of the
Spanish population [11]. Diagnosis is codified according
the Spanish version of the International Classification of
Diseases, 9th Revision, Clinical Modification (ICD-9-CM)
[12]. Hospital discharge data have been previously shown
to be an important source of information for assessing the
burden of diseases such as varicella, rotavirus or pneumo-
nia and different types of cancer [13-17]
All hospital discharges with a primary or secondary diag-
nosis of herpes zoster (ICD-9-MC codes 053.0–053.9)
during a 7-year period (1998–2004), were obtained. For
each case data were gathered on age, Region of hospitali-
zation, first and secondary diagnosis, type of discharge
(death, recovery, other) and length of hospital stay. Costs
related to hospitalization were estimated by using the
Diagnosis Related Groups (DRG) system, which classifies
hospitalizations into groups that are expected to generate
similar use of hospital resources. Classification is based
on diagnoses, procedures, age, presence of complications
and co-morbidities [18]. Each group has similar weight in
hospital costs and can be apply to each related patient.
GRDs calculations are made by 3 M with Core Grouping
System Software [19]
Statistical methods
The unit of analysis was the hospital admission. The aver-
age annual number of hospitalizations for herpes zoster
(ICD-9-CM codes 053, 053.0–053.9) in patients ≥ 30
years of age, annual hospitalization rate (annual number
of hospital admissions per 100,000 population), average
length of hospital stay (ALOS), mortality rate (annual
number of deaths at hospital per 100,000 population)
and case-fatality rate (annual number of deaths at hospi-
tal/annual number of hospital admissions; %) were calcu-
lated. The Spanish population obtained from the 1998–
2004 census projection and adjusted to the 97.7% of the
population covered by hospitals included in the CMBD
was used as denominator. It was assumed that the distri-
bution by age of the population covered by public hospi-
tals was equal to the distribution of the general
population. The age-standardized hospitalization rates
were calculated for the different Autonomous Regions by
direct standardization. The standard reference population
of the EU was used for this calculation. The frequency of
co-morbidities and complications related to herpes zoster
was assessed by studying the distribution of the co-exist-
ent and subsequent codes to HZ, respectively. The cost of
these hospitalizations for the health care system was cal-
culated by considering the diagnosis-related groups
(DRGs), the total cost and the number of discharges.
ANOVA was used for multiple comparisons. The post hoc
Bonferroni correction was used to adjust statistical signif-
icance for multiple comparisons. The individual cost of a
hospitalization was calculated by dividing the total
annual cost (all DRG costs per year) by the total number
of admissions per year.
Cases of herpes zoster were stratified by age group: 30–49
years; 50–59 years; 60–69 years; 70–79 years; ≥ 80 years.
Data were processed and analyzed using SPSS software for
personal computers (version 14.0; Chicago, Ill, USA). The
study was approved by the Research Ethics Committee of
the Hospital 12 de Octubre (Madrid).
Results
A total of 23,584 hospital discharges with a primary or
secondary diagnosis of herpes zoster were identified dur-
ing the 7-years study period (an annual average number of
3,369 admissions). The mean age (SD) of these patients
was 68.3 (15.5) years of age, respectively. Fifty-two per-
cent of the patients were men and more than 85% of these
hospitalizations were in population older than 50 years of
age (Table 1). The annual hospitalization rate for herpes
zoster was of 13.4 hospital admissions per 100,000 pop-
ulation ≥ 30 years of age. This rate increases with age
reaching a maximum in population ≥ 80 years of age
(54.3 admissions per 100,000 population) (Table 1).BMC Infectious Diseases 2009, 9:55 http://www.biomedcentral.com/1471-2334/9/55
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A total of 1,092 deaths occurred among patients hospital-
ized for herpes zoster during the study period (an average
of 156 deaths per year). The case-fatality rate was 4.6%
during the study period, being of 7.2% among patients ≥
80 years old (Figure 1). The mortality rate was 0.6 per
100,000 population, being of 3.9 per 100,000 population
among patients ≥ 80 years old (Figure 1). The average
length of stay in hospital was 12.9 days (SD 14.6) (Table
1).
Figure 2 shows the average annual hospitalization rate for
herpes zoster in the seventeen Autonomous Regions of
Spain. Navarra has the highest hospitalization rate (20.1
per 100,000 population) and Canary Islands the lowest
(6.1 per 100,000 population). The average length of hos-
pital stay ranged from 10 days in Murcia to 20 days in
Canary Islands.
Herpes zoster code was the first listed diagnosis in 27% of
the discharges. In the other 73%, the primary cause of
hospitalization (first listed diagnosis) was mainly respira-
tory diseases (24%) and cardiovascular diseases (19%).
When analysing first position diagnosis code, a 3.62 hos-
pitalization rate (per 100,000 population) was found,
with a mean age of 68 years old and a mortality rate of
0.06 deaths per 100,000 population. The case-fatality rate
was 1.68% and the hospitalization length of stay was 9.23
(SD 9.26).
Twenty-five percent of patients showed to have one or
more diagnosis of co-morbid illnesses: leukaemia, other
malignancies and HIV were the most frequent (9.6%,
8.4% and 6.5%, respectively), with HIV being the most
frequent comorbidity (40%) in the 30–49 year-old
patients.
Complications related with herpes zoster were present in
45% of admissions and neurological complications
(28.6%) were the most frequently documented condi-
tions in all age groups.
The mean cost of a herpes zoster related hospitalization
was  € 3,720. This figure was relatively stable among
groups of age (Table 1). Therefore, hospitalizations for
herpes zoster generate an annual expenditure in Spain of
€ 12,731,954. When studying separately primary diag-
nose code, the mean cost per HZ episode was € 3,200.
Discussion
Analysis of population-based hospital discharge data is a
feasible, simple and sensitive way to monitor the occur-
rence of some diseases and their epidemiology. However,
hospital discharge data have some limitations, including
some potential biases associated to coding or the fact that
a hospital discharge record represents a single hospital
admission, and so a single patient admitted more than
once will have multiple records [20]. In addition, it was
not possible to determine whether herpes zoster was the
main cause of the hospitalization. Other limitations are
the lack of data on disease severity, medication or use of
procedures, such as mechanical respiration, or intensive
care stay, all of which are important determinant of hos-
pitalizations usage and costs. [21] However, an outpatient
study of herpes zoster in which case finding was based on
diagnostic codes, including ICD-9 codes, found an 89%–
96% positive predictive value of a diagnostic code of her-
pes zoster. [22]
Rate of death and fatality rate in patients hospitalized with  herpes zoster by group of age in Spain (1998–2004) Figure 1
Rate of death and fatality rate in patients hospital-
ized with herpes zoster by group of age in Spain 
(1998–2004).
Table 1: Hospitalizations for herpes zoster per group of age
Age
(years)
Cases Hospitalization rates
(cases per 100,000 (IC95%))
Average length
of stay (days)(SD)
Average
costs
Total annual
costs (1999–2004)
30–49 3449 4.13 (3.76–4.49) 12.45 (16.38) 3,983.84 € 1,967,352€
50–59 2348 7.44 (7.14–7.75) 13.00 (16.41) 4,078.98 € 1,384,135€
60–69 4468 16.56 (16.07–17.04) 13.49 (16.52) 3,796.48 € 2,451,261€
70–79 7362 32.87 (32.12–33.62) 12.90 (13.57) 3,616.04 € 3,869,164€
>80 5957 54.33 (52.95–55.70) 12.59 (12.36) 3,500.53 € 3,060,044€
Total 23584 13.44 (13.27–13.61) 12.88 (14.62) 3,719.53 € 12,731,955€BMC Infectious Diseases 2009, 9:55 http://www.biomedcentral.com/1471-2334/9/55
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More than 23,584 hospitalizations for herpes zoster
occurred during the 1998–2004 period, which means an
annual hospitalization rate of 13.4 per 100,000 popula-
tion ≥ 30 years of age for herpes zoster. Our figures are
consistent with those found in other studies in USA and
Europe using population-based data including general
practitioner sentinel surveillance, hospitalisation data,
and death certificates. The existing data on the incidence
of hospitalization for herpes zoster in Spain is 8.4 per
100,000 population [13]. Studies in the United States and
England and Wales show an incidence of herpes zoster-
related hospitalizations of 16.1 and 4.4 per 100,000 pop-
ulation, respectively.[8,23] Mainly due to differences in
the Health National Systems and criteria for hospitaliza-
tion of adult patients.
Age-specific rate of hospitalizations increased sharply
with age, especially after the age of 50 years, reaching 54.3
hospitalizations per 100,000 persons at ≥ 80 years of age.
This finding matches with the pattern of incidence of her-
pes zoster described in developed countries, where most
of the burden of severe zoster occurs in adults ≥ 50 years
of age [24,25].
There were some differences among regions in relation to
the rate of hospitalizations. These differences may be
attributed to variability in the reporting system and cod-
ing, and also to factors related to the patient condition
(mainly age and comorbidity) and the health system
(availability of hospital beds per 100,000 population,
clinical procedures). The lower hospitalization rate in the
Canary Islands could be explained by its special geo-
graphic characteristics, as they are in a tropical area, where
the VZV seroprevalence is possibly lower than in temper-
ate areas.
Neurological conditions were the most frequent compli-
cation in patients hospitalized for herpes zoster. This has
been previously shown in a study carried out in Finland
[26]. Persons with underlying comorbidity, such as leu-
kaemia or HIV have an increased risk of presenting zoster-
related complications. Anyway, immunocompromised
patients will not be prevented by vaccination with the live
attenuated varicella-zoster virus vaccine, such admissions
might be minimally or non modified by a vaccine-based
prevention strategy.
Hospitalization rate, mortality rate and case-fatality rate
found for any diagnose position were four, ten and three-
fold those for HZ as first diagnosis position, respectively.
The hospitalization length of stay was 4 days shorter. This
indicates the importance of underlying co-morbidities,
that can increase the severity of a herpes zoster episode.
The cost for a primary diagnose of HZ was € 520 cheaper.
The estimated annual cost of hospitalizations for herpes
zoster in adults in Spain will be of 12.7 million €. This fig-
ure will be higher when indirect costs are also considered.
Conclusion
Herpes zoster is a costly disease that disproportionately
affects the elderly. It imposes an important burden of hos-
pitalizations and result in large cost expenses to the Span-
ish National Health System, especially in population
older than 50 years of age
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